Heel fat pad atrophy is an increasingly recognised cause of plantar heel pain, especially in older or high‑impact populations, and is frequently misdiagnosed as plantar fasciopathy. It involves structural and functional failure of the calcaneal fat pad, resulting in reduced shock absorption, focal overloading of the calcaneus, and characteristic bruised, central heel pain with weightbearing.
Anatomy and biomechanics of the heel fat pad
The plantar calcaneal fat pad (corpus adiposum) is a specialised fibro‑adipose structure that overlies the inferior surface of the calcaneus. It is organised into elastic fat chambers separated by fibrous septa that anchor to the periosteum, designed to resist shear and dissipate vertical ground reaction forces during gait. In a healthy adult, heel pad thickness is typically around 1–2 cm, with ultrasound studies reporting unloaded thickness close to 18–20 mm and significant but controlled compressibility under load. During walking, the heel can be exposed to forces of approximately 110% of body weight, rising to around 200% during running, which the fat pad normally attenuates. This mechanical role explains why subtle structural change can produce disproportionate symptoms.
Pathophysiology and aetiology
Heel fat pad atrophy reflects thinning, fragmentation, or displacement of the corpus adiposum accompanied by loss of elasticity and hydration. Micromechanical failure of the fibrous septa is thought to reduce structural integrity, impairing shock absorption and allowing higher peak plantar pressures directly over the calcaneus. Over time, repetitive high‑impact loading, such as running or jumping, and prolonged standing on hard surfaces drive cumulative microtrauma and wear, particularly when combined with inadequate footwear or barefoot loading on rigid substrates.
Multiple intrinsic and extrinsic factors contribute. Ageing leads to reduced collagen elasticity, loss of soft‑tissue moisture, and thinning or displacement of the fat pad, making heel fat pad syndrome more prevalent in older adults. Biomechanical factors, including altered arch alignment, high arches, and abnormal gait patterns, shift load toward the posterior calcaneus and increase local stress. A history of corticosteroid injection into or near the heel has been associated with fat pad breakdown, presumably via catabolic effects on collagen and adipose tissue. Systemic factors such as obesity and certain medical conditions further compromise tissue integrity and may accelerate thinning. Less commonly, acute trauma or a single episode of excessive heel strike can precipitate symptomatic structural failure.
Clinical presentation and differential diagnosis
Clinically, patients typically describe a deep, dull, “bruised” pain centred under the heel that is provoked by weightbearing and worsens on hard surfaces or when walking barefoot. Standing or walking for prolonged periods aggravates symptoms, whereas non‑weightbearing usually provides rapid relief. On examination, there is focal tenderness beneath the posterior‑central calcaneus, often slightly lateral to the midline, corresponding to the main weightbearing point at heel strike. The pad may feel thinned or less resilient on palpation compared to the contralateral side, and compressive testing may reproduce pain.
Differentiating heel fat pad atrophy from plantar fasciopathy is clinically important, as management priorities differ. Plantar fasciitis usually presents with medial calcaneal and proximal fascial tenderness and pronounced “first‑step” pain after rest, whereas fat pad pain is more central/posterior, often maximal during prolonged standing or impact and particularly severe when barefoot on firm ground. Radiology and ultrasound can assist: imaging in heel fat pad syndrome may demonstrate reduced fat pad thickness, altered echotexture, septal defects, fibrosis, or oedema within or around the pad, whereas plantar fasciopathy shows fascial thickening and entheseal changes. A scoping review suggests heel fat pad syndrome may be the second most common cause of plantar heel pain, yet is frequently overlooked or conflated with plantar fasciopathy in the literature and in practice.
Investigations
Although heel fat pad atrophy is primarily a clinical diagnosis, imaging can provide objective corroboration and help exclude other pathology. Ultrasound offers a practical method to quantify heel pad thickness in unloaded and loaded states and to assess compressibility, with studies reporting abnormal thinning and altered compressibility indices in symptomatic patients. MRI can demonstrate changes such as focal atrophy, fibrosis, oedema, and septal defects, alongside assessment of surrounding soft tissues and bone marrow. Radiographs may be useful to assess calcaneal spurs or other bony pathology but are less informative regarding fat pad quality. Objective measurement can be valuable in tracking progression and response to interventions in both clinical and research settings.
Conservative management
Management is initially conservative and centres on reducing peak plantar pressures while optimising overall foot biomechanics. Activity modification is foundational: patients are advised to reduce or temporarily cease high‑impact activities such as distance running and court sports, substituting with lower‑impact exercise where possible. Footwear education is crucial, emphasising supportive shoes with firm heel counters, appropriate arch support, and adequate heel cushioning; walking barefoot or in thin‑soled footwear on hard surfaces is discouraged. External devices—including cushioned socks, silicone or gel heel cups, and custom or semi‑custom insoles—aim to increase cushioning and, importantly, to contain and centralise the fat pad under the calcaneus.
Clinical taping techniques can be used to “cup” and reposition the pad beneath the heel, providing symptomatic relief and serving as a predictor of orthotic response. Physiotherapy or podiatry‑led rehabilitation often includes strengthening of intrinsic and extrinsic foot and ankle musculature, improving load sharing and dynamic stability, as well as targeted mobilisation of the rearfoot, talocrural joint, and plantar fascia to restore normal motion patterns. Adjunctive measures, such as short periods of icing and judicious use of oral or topical non‑steroidal anti‑inflammatories, may assist during acute exacerbations, although they do not address the underlying structural deficit. Importantly, repeated corticosteroid injection into the heel should be avoided in this population because of its association with further fat pad compromise.
Emerging interventional approaches and evidence gaps
For patients who remain significantly symptomatic despite optimised conservative care, several interventional strategies have been explored, though the evidence base remains limited. These include injectable fillers and heel fat pad augmentation via autologous fat grafting, which aim to restore volume and shock‑absorbing capacity. Clinical trial protocols investigating autologous fat transfer suggest that improving plantar cushioning may reduce peak plantar pressures, potentially lowering the risk of ulceration in high‑risk groups such as individuals with diabetes and bony prominence. Early case series and small studies report imaging‑confirmed changes in fat pad morphology, including atrophy, fibrosis, and oedema, but there remains a “glaring absence” of robust controlled trials evaluating the long‑term efficacy and durability of commonly used conservative and surgical interventions.
Consequently, current best practice emphasises accurate diagnosis, comprehensive mechanical off‑loading, and optimisation of global foot function, while recognising that definitive regenerative solutions are still under investigation. From a clinical perspective, heel fat pad atrophy underscores the importance of viewing plantar heel pain as a heterogeneous symptom complex rather than a monolithic “plantar fasciitis” entity, demanding careful localisation of pain, biomechanical assessment, and tailored intervention.